- Home
- ESTC vs MDGL Comparison
ESTC vs MDGL Comparison
Compare ESTC & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESTC | MDGL |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 10.0B |
| IPO Year | 2018 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ESTC | MDGL |
|---|---|---|
| Price | $50.18 | $446.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 27 | 12 |
| Target Price | $94.08 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 2.1M | 246.1K |
| Earning Date | 02-26-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,483,296,000.00 | $180,133,000.00 |
| Revenue This Year | $19.06 | $58.28 |
| Revenue Next Year | $13.42 | $46.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.04 | N/A |
| 52 Week Low | $49.55 | $265.00 |
| 52 Week High | $98.25 | $615.00 |
Technical Indicators
Market Signals| Indicator | ESTC | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 36.16 | 47.26 |
| Support Level | N/A | $416.43 |
| Resistance Level | $65.04 | $446.51 |
| Average True Range (ATR) | 2.30 | 15.99 |
| MACD | 0.36 | 3.64 |
| Stochastic Oscillator | 3.34 | 53.39 |
Price Performance
Historical ComparisonAbout ESTC Elastic N.V.
Elastic is a software company that specializes in AI-search, observability, and security deployments. Its search division offers both traditional keyword search and vector search methods to enable more context-aware querying. The software has open-source origins but generates revenue through valuable add-ons, including simplified data orchestration and server scaling techniques.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.